Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Limited has informed BSE that it has published the extract of its Unaudited Financial Results for the quarter and half-year ended September 30, 2025 in newspapers as required under SEBI Regulation 47. The advertisement appeared in Free Press Journal (English) and Navbharat (Hindi) on November 17, 2025. BSE Scrip Code is 524322. The Managing Director, Nanjappan Aravind (DIN: 01895602), signed the filing digitally. This is a routine regulatory compliance disclosure informing the exchange that the financial results, which were already filed earlier, have now been published in the press as mandated.
This is a procedural disclosure with no new financial information. No material impact on shareholders or stock price; the actual results were already filed earlier and remain unchanged by this newspaper publication.